IBDEI11Z ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18567,1,5,0)
 ;;=5^205.32
 ;;^UTILITY(U,$J,358.3,18567,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,18568,0)
 ;;=205.31^^102^1191^44
 ;;^UTILITY(U,$J,358.3,18568,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18568,1,4,0)
 ;;=4^MYELOID SARCOMA IN REMISSION
 ;;^UTILITY(U,$J,358.3,18568,1,5,0)
 ;;=5^205.31
 ;;^UTILITY(U,$J,358.3,18568,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,18569,0)
 ;;=202.08^^102^1191^45
 ;;^UTILITY(U,$J,358.3,18569,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18569,1,4,0)
 ;;=4^NODULAR LYMPHOMA NODES MULT
 ;;^UTILITY(U,$J,358.3,18569,1,5,0)
 ;;=5^202.08
 ;;^UTILITY(U,$J,358.3,18569,2)
 ;;=^267447
 ;;^UTILITY(U,$J,358.3,18570,0)
 ;;=202.78^^102^1191^46
 ;;^UTILITY(U,$J,358.3,18570,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18570,1,4,0)
 ;;=4^PERIPHERAL T-CELL LYMPHOMA
 ;;^UTILITY(U,$J,358.3,18570,1,5,0)
 ;;=5^202.78
 ;;^UTILITY(U,$J,358.3,18570,2)
 ;;=^335236
 ;;^UTILITY(U,$J,358.3,18571,0)
 ;;=203.11^^102^1191^48
 ;;^UTILITY(U,$J,358.3,18571,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18571,1,4,0)
 ;;=4^PLASMA CELL LEUK,REMISSION
 ;;^UTILITY(U,$J,358.3,18571,1,5,0)
 ;;=5^203.11
 ;;^UTILITY(U,$J,358.3,18571,2)
 ;;=^267517
 ;;^UTILITY(U,$J,358.3,18572,0)
 ;;=203.12^^102^1191^47
 ;;^UTILITY(U,$J,358.3,18572,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18572,1,4,0)
 ;;=4^PLASMA CELL LEUK,RELAPSE
 ;;^UTILITY(U,$J,358.3,18572,1,5,0)
 ;;=5^203.12
 ;;^UTILITY(U,$J,358.3,18572,2)
 ;;=^336463
 ;;^UTILITY(U,$J,358.3,18573,0)
 ;;=200.58^^102^1191^49
 ;;^UTILITY(U,$J,358.3,18573,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18573,1,4,0)
 ;;=4^PRIM CNS LYMPHOMA MULTI
 ;;^UTILITY(U,$J,358.3,18573,1,5,0)
 ;;=5^200.58
 ;;^UTILITY(U,$J,358.3,18573,2)
 ;;=^335212
 ;;^UTILITY(U,$J,358.3,18574,0)
 ;;=200.08^^102^1191^50
 ;;^UTILITY(U,$J,358.3,18574,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18574,1,4,0)
 ;;=4^RETICULOSARCOMA MULT
 ;;^UTILITY(U,$J,358.3,18574,1,5,0)
 ;;=5^200.08
 ;;^UTILITY(U,$J,358.3,18574,2)
 ;;=^267349
 ;;^UTILITY(U,$J,358.3,18575,0)
 ;;=202.28^^102^1191^51
 ;;^UTILITY(U,$J,358.3,18575,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18575,1,4,0)
 ;;=4^SEZARY'S DISEASE MULT
 ;;^UTILITY(U,$J,358.3,18575,1,5,0)
 ;;=5^202.28
 ;;^UTILITY(U,$J,358.3,18575,2)
 ;;=^267463
 ;;^UTILITY(U,$J,358.3,18576,0)
 ;;=200.88^^102^1191^28
 ;;^UTILITY(U,$J,358.3,18576,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18576,1,4,0)
 ;;=4^MIXED LYMPHOSARC MULT
 ;;^UTILITY(U,$J,358.3,18576,1,5,0)
 ;;=5^200.88
 ;;^UTILITY(U,$J,358.3,18576,2)
 ;;=^267373
 ;;^UTILITY(U,$J,358.3,18577,0)
 ;;=279.2^^102^1192^1
 ;;^UTILITY(U,$J,358.3,18577,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18577,1,4,0)
 ;;=4^COMBINED IMMUNITY DEFIC
 ;;^UTILITY(U,$J,358.3,18577,1,5,0)
 ;;=5^279.2
 ;;^UTILITY(U,$J,358.3,18577,2)
 ;;=^267967
 ;;^UTILITY(U,$J,358.3,18578,0)
 ;;=279.11^^102^1192^2
 ;;^UTILITY(U,$J,358.3,18578,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18578,1,4,0)
 ;;=4^DIGEORGE'S SYNDROME
 ;;^UTILITY(U,$J,358.3,18578,1,5,0)
 ;;=5^279.11
 ;;^UTILITY(U,$J,358.3,18578,2)
 ;;=^34561
 ;;^UTILITY(U,$J,358.3,18579,0)
 ;;=272.7^^102^1192^3
 ;;^UTILITY(U,$J,358.3,18579,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18579,1,4,0)
 ;;=4^LIPIDOSES
 ;;^UTILITY(U,$J,358.3,18579,1,5,0)
 ;;=5^272.7
 ;;^UTILITY(U,$J,358.3,18579,2)
 ;;=^71139
 ;;^UTILITY(U,$J,358.3,18580,0)
 ;;=277.5^^102^1192^4
 ;;^UTILITY(U,$J,358.3,18580,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18580,1,4,0)
 ;;=4^MUCOPOLYSACCHARIDOSIS
 ;;^UTILITY(U,$J,358.3,18580,1,5,0)
 ;;=5^277.5
 ;;^UTILITY(U,$J,358.3,18580,2)
 ;;=^79518
 ;;^UTILITY(U,$J,358.3,18581,0)
 ;;=279.12^^102^1192^5
 ;;
 ;;$END ROU IBDEI11Z
